1. Hendrickson M, Martinez A, Ross J, Kempson R, Eifel P. Uterine papillary serous carcinoma, a highly malignant form of endometrial adenocarcinoma. Am J Surg Path 1982; 6: 93-108.

2. Bokhman J. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.

3. Deligdisch L, Holinka C. Endometrial carcinoma: two diseases? Cancer Detect Prev 1987; 10: 237-246.

4. Sherman ME, Bur ME, Kurman RJ. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 1995; 26: 1268-1274.

5. Sherman ME. Theories of endometrial carcinogenesis: a multidisciplinary approach. Mod Pathol 2000; 13(3): 295-308.

6. Parazzini F, La Vecchia C, Bocciolone L, Franceschi S. The epidemiology of endometrial cancer. Gynecol Oncol 1991; 41: 1-16.

7. Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002; 55(5): 326-331.

8. Mutter GL. PTEN, a protean tumor suppressor. Am J Pathol 2001; 158: 1895-1898.

9. Esteller M, Levine R, Baylin SB, Ellenson LH, Herman JG. MLH1 promoter hypermethylation is associated with the microsatellite instability phenotype in sporadic endometrial carcinomas. Oncogene 1998; 17: 2413-2417.

10. Faquin WC, Fitzgerald JT, Lin MC, Boynton KA, Muto MG, Mutter GL. Sporadic microsatellite instability is specific to neoplastic and preneoplastic endometrial tissues. Am J Clin Pathol 2000; 113(4): 576-582.

11. Basil JB, Goodfellow PJ, Rader JS, Mutch DG, Herzog TJ. Clinical significance of microsatellite instability in endometrial carcinoma. Cancer 2000; 89(8): 1758-1764.

12. Aaltonen LA, Peltomaki P, Mecklin JP, et al. Replication errors in benign and malignant tumors from hereditary nonpolyposis colorectal cancer patients. Cancer Res 1994; 54: 1645-1648.

13. Lynch HT, Casey MJ, Shaw TG, Lynch JF. Hereditary Factors in Gynecologic Cancer. Oncologist 1998; 3(5): 319-338.

14. Hertig A, Sommers S. Genesis of endometrial carcinoma. I. Study of prior biopsies. Cancer 1949; 2: 946-956.

15. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Uterine corpus. Histological Typing of Female Genital Tract Tumors. New York, Springer-Verlag, 1994, pp. 13-31.

16. Kurman R, Kaminski P, Norris H. The behavior of endometrial hyperplasia: a long term study of "untreated" hyperplasia in 170 patients. Cancer 1985; 56: 403-412.

17. Mutter GL, Boynton KA, Faquin WC, Ruiz RE, Jovanovic AS. Allelotype mapping of unstable microsatellites establishes direct lineage continuity between endometrial precancers and cancer. Cancer Res 1996; 56: 4483-4486.

18. Mutter GL, Baak JPA, Crum CP, Richart RM, Ferenczy A, Faquin WC. Endometrial precancer diagnosis by histopathology, clonal analysis, and computerized morphometry. J Pathol 2000; 190: 462-469.

19. Risinger JI, Hayes AK, Berchuck A, Barrett JC. PTEN/MMAC1 mutations in endometrial cancers. Cancer Res 1997; 57(21): 4736-4738.

20. Mutter GL, Lin MC, Fitzgerald JT, et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924-930.

21. Stambolic V, Tsao MS, Macpherson D, Suzuki A, Chapman WB, Mak TW. High incidence of breast and endometrial neoplasia resembling human Cowden syndrome in pten+/- mice. Cancer Res 2000; 60(13): 3605-3611.

22. Mutter GL, Ince TA, Baak JPA, Kust G, Zhou X, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001; 61: 4311-4314.

23. Goodfellow PJ, Buttin BM, Herzog TJ, et al. Prevalence of defective DNA mismatch repair and MSH6 mutation in an unselected series of endometrial cancers. Proc Natl Acad Sci USA 2003; 100(10): 5908-5913.

24. Esteller M, Catasus L, Matias-Guiu X, et al. hMLH1 Promoter Hypermethylation Is an Early Event in Human Endometrial Tumorigenesis. Am J Pathol 1999; 155(5): 1767-1772.

25. Enomoto T, Inoue M, Perantoni A, et al. K-ras activation in premalignant and malignant epithelial lesions of the human uterus. Cancer Res 1991; 51: 5304-5314.

26. Duggan BD, Felix JC, Muderspach LI, Tsao J-L, Shibata DK. Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res 1994; 54: 1604-1607.

27. Mutter GL, Wada H, Faquin W, Enomoto T. K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis. Mol Pathol 1999; 52: 257-262.

28. Matias-Guiu X, Catasus L, Bussaglia E, et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32(6): 569-577.

29. Silverberg SG, Mutter GL, Kurman RJ, Kubik-Huch RA, Nogales F, Tavassoli FA. Tumors of the uterine corpus: epithelial tumors and related lesions. in: WHO Classification of Tumors: Pathology and Genetics of Tumors of the Breast and Female Genital Organs (Tavassoli FA, Stratton MR, eds.), IARC Press, Lyon, France, 2003, pp. 221-232.

30. Mutter GL, The Endometrial Collaborative Group. Endometrial intraepithelial neoplasia (EIN): Will it bring order to chaos? Gynecol Oncol 2000; 76: 287-290.

31. Mutter GL. Histopathology of genetically defined endometrial precancers. Int J Gynecol Pathol 2000; 19: 301-309.

32. Mutter GL, Ince TA. Molecular Pathogenesis of Endometrial Cancer. in: Uterine Cancer: American Cancer Society Atlas of Clinical Oncology (Fuller A, Seiden MV, Young R, eds.), Hamilton, Ontario, Canada, B.C.Decker, 2003, pp. 10-21.

33. Mutter GL, Chaponot M, Fletcher J. A PCR assay for non-random X chromosome inactivation identifies monoclonal endometrial cancers and precancers. Am J Pathol 1995; 146: 501-508.

34. Mutter GL, Boynton KA. X chromosome inactivation in the normal female genital tract: Implications for identification of neoplasia. Cancer Res 1995; 55: 5080-5084.

35. Jovanovic AS, Boynton KA, Mutter GL. Uteri of women with endometrial carcinoma contain a histopathologic spectrum of monoclonal putative precancers, some with microsatellite instability. Cancer Res 1996; 56: 1917-1921.

36. Baak JPA, Nauta J, Wisse-Brekelmans E, Bezemer P. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol 1988; 154: 335-341.

37. Baak JPA. Manual of Quantitative Pathology in Cancer Diagnosis and Prognosis. New York: Springer-Verlag, 1991 p. 332-338.

38. Hecht JL, Ince TA, Baak JP, Baker HE, Ogden MW, Mutter GL. Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis. Mod Pathol 2005; 18: 324-330.

39. Dunton C, Baak J, Palazzo J, van Diest P, McHugh M, Widra E. Use of computerized morphometric analyses of endometrial hyperplasias in the prediction of coexistent cancer. Am J Obstet Gynecol 1996; 174: 1518-1521.

40. Orbo A, Baak JP, Kleivan I, et al. Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol 2000; 53(9): 697-703.

41. Baak JP, Orbo A, van Diest PJ, et al. Prospective multicenter evaluation of the morphometric D-score for prediction of the outcome of endometrial hyperplasias. Am J Surg Pathol 2001; 25(7): 930-935.

42. Baak JPA, Mutter GL, Robboy S, et al. In endometrial hyperplasias, the molecular-genetics and mor-phometry-based EIN classification more accurately predicts cancer-progression than the WHO94. Cancer 2005; 103(11).

43. Potischman N, Hoover R, Briton L, et al. Case control study of exogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996; 88: 1127-1135.

44. Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1996; 275: 370-375.

45. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001; 84(7): 975-981.

46. Grimes DA, Economy KE. Primary prevention of gynecologic cancers. Am J Obstet Gynecol 1995; 172: 227-235.

47. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 1999; 10(4): 277-284.

48. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Ziebold U, Eng C. Changes in endometrial PTEN expression throughout the human menstrual cycle. J Clin Endocrinol Metab 2000; 85: 2334-2338.

49. Zheng W, Baker HE, Mutter GL. Involution of PTEN-Null Endometrial Glands with Progestin Therapy. Gynecol Oncol 2004; 92: 1008-1013.

50. Sherman ME, Sturgeon S, Brinton L, Kurman RJ. Endometrial cancer chemoprevention: implications of diverse pathways of carcinogenesis. J Cell Biochem 1995; 59(Suppl 23): 160-164.

51. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 cases and review of the literature. Mod Pathol 2000; 13(4): 379-388.

52. Zheng W, Khurana R, Farahmand S, Wang Y, Zhang ZF, Felix JC. p53 immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. Am J Surg Pathol 1998; 22(12): 1463-1473.

53. Sherman ME, Bitterman P, Rosenshein NB, Delgado G, Kurman RJ. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol 1992; 16(6): 600-610.

54. Ambros RA, Sherman ME, Zahn CM, Bitterman P, Kurman RJ. Endometrial intraepithelial carcinoma: A distinctive lesion specifically associated with tumors displaying serous differentiation. Hum Pathol 1995; 26: 1260-1267.

55. Wheeler DT, Bell KA, Kurman RJ, Sherman ME. Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation. Am J Surg Pathol 2000; 24(6): 797-806.

56. Zheng W, Liang SX, Yu H, Rutherford T, Chambers SK, Schwartz PE. Endometrial glandular dys-plasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features. Int J Surg Pathol 2004; 12(3): 207-223.

57. Liang SX, Chambers SK, Cheng L, Zhang S, Zhou Y, Zheng W. Endometrial glandular dysplasia: a putative precursor lesion of uterine papillary serous carcinoma. Part II: molecular features. Int J Surg Pathol 2004; 12(4): 319-331.

58. Berchuck A, Boyd J. Molecular basis of endometrial cancer. Cancer 1995; 76(Suppl): 2034-2040.

Natural Cures For Menopause

Natural Cures For Menopause

Are Menopause Symptoms Playing Havoc With Your Health and Relationships? Are you tired of the mood swings, dryness, hair loss and wrinkles that come with the change of life? Do you want to do something about it but are wary of taking the estrogen or antidepressants usually prescribed for menopause symptoms?

Get My Free Ebook

Post a comment